Ajani J A, Ryan B, Rich T A, McMurtrey M, Roth J A, DeCaro L, Levin B, Mountain C
UT M.D. Anderson Cancer Center, Houston 77030-4096.
Eur J Cancer. 1992;28A(4-5):880-4. doi: 10.1016/0959-8049(92)90140-w.
We evaluated the feasibility of six courses of chemotherapy in 34 consecutive patients with localised squamous cell carcinoma of the oesophagus. All 32 evaluable patients first received at least two courses of chemotherapy. There were 18 patients with resectable carcinomas who underwent surgery and 14 patients with unresectable carcinomas who received definitive chemoradiotherapy. After two courses of 5-fluorouracil and cisplatin 21 (66%) of 32 patients had either a complete or major response. A median of five courses (range, 1-6 courses) was administered. 17 out of 18 (94%) patients with resectable carcinoma had a 'curative' resection (negative proximal, distal, and radial margins by histopathology in an en-block resection specimen) and 2 patients had a complete pathological response. The median survival duration of all patients was 28 months (range, 2-46+ months). The median survival duration of 14 patients with unresectable carcinoma was 23 months (range, 8-36+ months), and the median survival duration of 18 patients with resectable carcinoma has not been reached at a median follow-up of 24+ months (range, 10+ to 46+ months). No deaths occurred because of chemotherapy or chemoradiation therapy. Our data suggest that prolonged chemotherapy is feasible in patients with locoregional squamous carcinoma of the oesophagus. An ongoing controlled trial will determine the contribution of chemotherapy to patients' survival.
我们评估了连续34例局限性食管鳞状细胞癌患者接受六个疗程化疗的可行性。所有32例可评估患者首先接受了至少两个疗程的化疗。其中18例可切除癌患者接受了手术,14例不可切除癌患者接受了根治性放化疗。在接受两个疗程的5-氟尿嘧啶和顺铂治疗后,32例患者中有21例(66%)出现完全缓解或主要缓解。化疗疗程中位数为五个疗程(范围1 - 6个疗程)。18例可切除癌患者中有17例(94%)进行了“根治性”切除(整块切除标本的组织病理学检查显示近端、远端和径向切缘阴性),2例患者出现完全病理缓解。所有患者的中位生存时间为28个月(范围2 - 46 +个月)。14例不可切除癌患者的中位生存时间为23个月(范围8 - 36 +个月),18例可切除癌患者在中位随访24 +个月(范围10 +至46 +个月)时,中位生存时间尚未达到。未发生因化疗或放化疗导致的死亡。我们的数据表明,延长化疗对局部区域食管鳞状癌患者是可行的。一项正在进行的对照试验将确定化疗对患者生存的贡献。